{
    "organizations": [],
    "uuid": "7201cd9c6681a437ef77807cf7102c5fc21f64bd",
    "author": "",
    "url": "https://www.reuters.com/article/brief-obseva-reports-positive-topline-re/brief-obseva-reports-positive-topline-results-from-implant2-phase-3-clinical-trial-of-nolasiban-in-ivf-idUSASB0C7DG",
    "ord_in_thread": 0,
    "title": "BRIEF-Obseva Reports Positive Topline Results From Implant2 Phase 3 Clinical Trial Of Nolasiban In IVF",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 26 (Reuters) - Obseva Sa:\n* OBSEVA SA REPORTS POSITIVE TOPLINE RESULTS FROM IMPLANT2 PHASE 3 CLINICAL TRIAL OF NOLASIBAN IN IVF\n* OBSEVA SA - ‍NOLASIBAN WAS WELL TOLERATED​\n* OBSEVA SA - FOLLOW-UP DATA FROM IMPLANT2 STUDY WILL INCLUDE LIVE BIRTH RATE, AND 28-DAY NEONATAL SAFETY, EXPECTED TO BE REPORTED IN Q4 OF 2018\n* OBSEVA SA - ‍IN ET D3 SUBGROUP, THERE WAS A STATISTICALLY NON-SIGNIFICANT 3.1% ABSOLUTE INCREASE IN FAVOR OF NOLASIBAN​\n* OBSEVA SA - SIX-MONTH INFANT FOLLOW-UP FROM IMPLANT2 STUDY IS EXPECTED TO BE AVAILABLE IN 2019\n* OBSEVA SA - ‍SAFETY PROFILE OF NOLASIBAN WAS ALSO SIMILAR TO PLACEBO​\n* OBSEVA SA - ‍NONE OF SERIOUS ADVERSE EVENTS WERE REPORTED TO BE RELATED TO TREATMENT​\n* OBSEVA SA - ‍IN ET D3 SUBGROUP, THERE WAS 14.0% RELATIVE INCREASE IN ONGOING PREGNANCY RATE AFTER ADMINISTRATION OF NOLASIBAN VERSUS PLACEBO​\n* OBSEVA SA - ‍IN ET D5 SUBGROUP, THERE WAS RELATIVE INCREASE IN ONGOING PREGNANCY RATE OF 32% AFTER ADMINISTRATION OF NOLASIBAN VERSUS PLACEBO​\n* OBSEVA SA - ‍IN ET D5 SUBGROUP, ABSOLUTE INCREASE WAS 11.2% IN FAVOR OF NOLASIBAN​ Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-26T14:40:00.000+02:00",
    "crawled": "2018-02-26T14:57:10.016+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "obseva",
        "sa",
        "obseva",
        "sa",
        "report",
        "positive",
        "topline",
        "result",
        "implant2",
        "phase",
        "clinical",
        "trial",
        "nolasiban",
        "ivf",
        "obseva",
        "sa",
        "well",
        "obseva",
        "sa",
        "data",
        "implant2",
        "study",
        "include",
        "live",
        "birth",
        "rate",
        "neonatal",
        "safety",
        "expected",
        "reported",
        "q4",
        "obseva",
        "sa",
        "et",
        "d3",
        "subgroup",
        "statistically",
        "absolute",
        "increase",
        "favor",
        "obseva",
        "sa",
        "infant",
        "implant2",
        "study",
        "expected",
        "available",
        "obseva",
        "sa",
        "profile",
        "nolasiban",
        "also",
        "similar",
        "obseva",
        "sa",
        "serious",
        "adverse",
        "event",
        "reported",
        "related",
        "obseva",
        "sa",
        "et",
        "d3",
        "subgroup",
        "relative",
        "increase",
        "ongoing",
        "pregnancy",
        "rate",
        "administration",
        "nolasiban",
        "versus",
        "obseva",
        "sa",
        "et",
        "d5",
        "subgroup",
        "relative",
        "increase",
        "ongoing",
        "pregnancy",
        "rate",
        "administration",
        "nolasiban",
        "versus",
        "obseva",
        "sa",
        "et",
        "d5",
        "subgroup",
        "absolute",
        "increase",
        "favor",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}